Cargando…

Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats

BACKGROUND: Although dopamine D(2) receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia, there is an identified relationship between the utilization of D(2)-like R agonists and the progress of myocardial inj...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fouad Shalaby, Mohammed, Latif, Hekma A. Abd El, Yamani, Mohamed El, Galal, May Ahmed, Kamal, Sherifa, Sindi, Ikhlas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577162/ https://www.ncbi.nlm.nih.gov/pubmed/34777640 http://dx.doi.org/10.1016/j.curtheres.2021.100647

Ejemplares similares

Corrigendum to ``Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats'' [Current Therapeutic Research Volume 95, 2021, 100647]
por: Shalaby, Mohammed Fouad, et al.
Publicado: (2022)

Therapeutic activity of sarpogrelate and dopamine D(2) receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes
por: Fouad Shalaby, Mohammed Ahmed, et al.
Publicado: (2021)

Bromocriptine or cabergoline induced pituitary apoplexy: Rare but life-threatening catastrophe
por: Singh, Pratibha, et al.
Publicado: (2011)

Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma
por: Menon, Lakshmi P., et al.
Publicado: (2021)

Bromocriptine or cabergoline-induced cerebrospinal fluid rhinorrhea: A life-threatening complication during management of prolactinoma
por: Singh, Pratibha, et al.
Publicado: (2011)

Arabic gum ameliorates systemic modulation in Alloxan monohydrate-induced diabetic rats
por: Ibrahim, Rasha Mohammed, et al.
Publicado: (2023)

Bromocriptine in type 2 diabetes mellitus
por: Shivaprasad, C., et al.
Publicado: (2011)

Chronic cluster‐like headache in a patient with a macroprolactinoma presenting with falsely low prolactin levels: bromocriptine versus cabergoline?
por: Pineyro, Maria M., et al.
Publicado: (2017)

Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively
por: Tang, Chao, et al.
Publicado: (2019)

Aspirination of α-Aminoalcohol (Sarpogrelate M1)
por: Park, Sunhwa, et al.
Publicado: (2016)

Protective role of Phyllanthusfraternus in alloxan-induced diabetes in rats
por: Singh, Hasandeep, et al.
Publicado: (2020)

THE EFFECT OF ALLOXAN DIABETES ON EXPERIMENTAL CHOLESTEROL ATHEROSCLEROSIS IN THE RABBIT : I. THE INHIBITION OF EXPERIMENTAL CHOLESTEROL ATHEROSCLEROSIS IN ALLOXAN DIABETES II. THE EFFECT OF ALLOXAN DIABETES ON THE RETROGRESSION OF EXPERIMENTAL CHOLESTEROL ATHEROSCLEROSIS
por: Duff, G. Lyman, et al.
Publicado: (1949)

Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes
por: Ramteke, Karuna Balwant, et al.
Publicado: (2011)

The influence of alloxan diabetes on experimental cancer.
por: Garvie, W. H.
Publicado: (1968)

Alloxan: An unpredictable drug for diabetes induction?
por: Misra, Monika, et al.
Publicado: (2012)

Evaluation of metformin performance on alloxan-induced diabetic rabbits
por: Yasin, Youssef Shakuri, et al.
Publicado: (2022)

Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
por: Gaziano, J. Michael, et al.
Publicado: (2012)

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
Publicado: (2015)

Novel Trajectories of Bromocriptine Antidiabetic Action: Leptin-IL-6/ JAK2/p-STAT3/SOCS3, p-IR/p-AKT/GLUT4, PPAR-γ/Adiponectin, Nrf2/PARP-1, and GLP-1
por: Reda, Enji, et al.
Publicado: (2018)

Suppression of high lipid diet induced by atherosclerosis sarpogrelate
por: Xu, Yan-Jun, et al.
Publicado: (2012)

Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes
por: Mahajan, Rajiv
Publicado: (2009)

Experimental Cerebral Mucormycosis in Rabbits with Alloxan Diabetes
por: Bauer, Heinz, et al.
Publicado: (1955)

Vestibular function for children with insulin dependent diabetes using cervical vestibular evoked myogenic potentials testing
por: Hamed, Sherifa Ahmed, et al.
Publicado: (2022)

Sarpogrelate hydrochloride ameliorates diabetic nephropathy associated with inhibition of macrophage activity and inflammatory reaction in db/db mice
por: Lee, Eun Soo, et al.
Publicado: (2017)

THE EFFECT OF ALLOXAN DIABETES ON EXPERIMENTAL CHOLESTEROL ATHEROSCLEROSIS IN THE RABBIT : III. THE MECHANISM OF THE INHIBITION OF EXPERIMENTAL CHOLESTEROL ATHEROSCLEROSIS IN ALLOXAN-DIABETIC RABBITS
por: Duff, G. Lyman, et al.
Publicado: (1950)

THE EFFECT OF ALLOXAN DIABETES ON EXPERIMENTAL CHOLESTEROL ATHEROSCLEROSIS IN THE RABBIT : IV. THE EFFECT OF INSULIN THERAPY ON THE INHIBITION OF ATHEROSCLEROSIS IN THE ALLOXAN-DIABETIC RABBIT
por: Duff, G. Lyman, et al.
Publicado: (1954)

A validated LC–MS/MS method for analysis of Cabergoline in human plasma with its implementation in a bioequivalent study: investigation of method greenness
por: Shalaby, Khaled, et al.
Publicado: (2022)

Antidiabetic Activity of Vinca rosea Extracts in Alloxan-Induced Diabetic Rats
por: Ahmed, Mohammed Fazil, et al.
Publicado: (2010)

Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice
por: Park, Kyung-Yeon, et al.
Publicado: (2016)

The Role of ERK1/2 Activation in Sarpogrelate-Mediated Neuroprotection
por: Ku, Cristy A., et al.
Publicado: (2018)

Diabetes mellitus remission in three cats with hypersomatotropism after cabergoline treatment
por: Miceli, Diego D, et al.
Publicado: (2021)

Diabetes mellitus remission in a cat with hyperadrenocorticism after cabergoline treatment
por: Miceli, Diego D, et al.
Publicado: (2021)

Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study)
por: Nomura, Shosaku, et al.
Publicado: (2018)

Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
por: Missale, C., et al.
Publicado: (1995)

STUDIES ON GLYCOGEN NEPHROSIS IN ALLOXAN-TREATED DIABETIC RATS
por: Curtis, G. W., et al.
Publicado: (1947)

Novel usage of sarpogrelate hydrochloride in patients with allergy-related variant angina
por: Noma, Kensuke, et al.
Publicado: (2012)

Prediction of response to bromocriptine in acromegaly.
por: Atkinson, A. B., et al.
Publicado: (1978)

Repurposing of Bromocriptine for Cancer Therapy
por: Seo, Ean-Jeong, et al.
Publicado: (2018)

Central Hyperthermia Treated with Bromocriptine
por: Natteru, P., et al.
Publicado: (2017)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_oibnua7dipgn8rmktclo3sagd6